97% of drug candidates in oncology fail in clinical trials. HCS Pharma has developed human 3D cellular model including the matricial microenvironment, in order to better select drug candidates. This model is available for High Content Screening as a service on our Robotic Platform.

BIOMIMESYS® Oncology allows the long-term culture of colon cancer cells and thus chronic treatment with repeated doses, more relevant in the field of anticancer therapy assessment.

